Patient Selection

On-Demand Webinar
HCP Resources Page
image
Description
In this informative webinar, Barbara Levy, MD, and Todd Rumsey, MD, share their expertise on the Cerene Cryotherapy Device, a groundbreaking treatment for premenopausal women with heavy menstrual bleeding. This session offers a deep dive into the patient selection criteria for Cerene, emphasizing its role in providing relief from heavy periods. The webinar is a must-watch for healthcare professionals looking to enhance their understanding of endometrial cryoablation and its application in a clinical setting. Key Takeaways
  1. Advanced Patient Comfort and Satisfaction with Cerene: The webinar emphasizes the significant improvements the Cerene Cryotherapy Device offers in patient comfort and satisfaction. Dr. Levy and Dr. Rumsey discuss the device's ease of use and its effectiveness in reducing discomfort during and after the procedure, a notable advancement over previous technologies.
  2. Importance of Accurate Patient Selection: The discussion focuses on the critical aspects of selecting the right patients for Cerene treatment. The speakers delve into various factors that influence this decision, including the patient's medical history, suitability for non-hormonal treatments, and the overall goal of reducing heavy menstrual bleeding without major surgery.
  3. Practical Insights into Cerene's Application: The webinar provides practical insights into the use of Cerene for endometrial ablation. It covers the procedural aspects, such as the benefits of patient participation and visual feedback during the procedure, and the cost-effectiveness of this minimally invasive approach. The session also addresses Cerene’s  role in expanding treatment options for patients.
Complete the Form Below to View
Now Playing
Video Library
Rhonda Schafer-McLean, MD and her patient, Brooke, discuss how and why the Cerene Cryotherapy Device was the right treatment option for Brooke’s heavy menstrual bleeding symptoms.
GYN experts, Taraneh Shirazian, MD, Richard Salter, MD and Barbara Levy, MD, explore how women’s health professionals can make heavy menstrual bleeding care more patient-centered with new innovations in cryotherapy.
Barbara Levy, MD moderates a discussion with Geoffrey Bowers, MD and Leslie Hansen Lindner, MD on their insights on the evolution of endometrial ablation and how innovations in cryotherapy may reshape thinking around heavy menstrual bleeding treatment.
A compilation of physician perspectives on the treatment of heavy menstrual bleeding and the Cerene Cryotherapy Device. (4 minutes)
Barbara Levy, MD discusses the treatment of heavy menstrual bleeding and the Cerene Cryotherapy Device. (4 minutes)
James Greenberg, MD and Barbara Levy, MD discuss the implications from recent and historical publications on the rates of hysterectomy after an endometrial ablation.
James Coad, MD and Andrew Brill, MD discuss the science and benefits of cryotherapy for endometrial ablation.
Barbara Levy, MD and Todd Rumsey, MD discuss patient selection criteria for the Cerene Cryotherapy Device (27 minutes).
Barbara Levy, MD along with panelists Robert Rubino, MD, Richard Salter, MD, and Shannon Smith, MD provide insights into the management of menorrhagia. (59 minutes)
Barbara Levy, MD and Gerard Reilly, MD discuss how new innovations in cryotherapy are transforming the treatment of heavy menstrual bleeding. (45 minutes)

Important Safety Information

Cerene® Cryotherapy Device is indicated to ablate the endometrial lining of the uterus in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete. Pregnancy following the Cerene procedure can be dangerous; therefore, contraception must be used until menopause. The Cerene procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Cerene Cryotherapy Device. Temporary side effects may include cramping, nausea, vomiting, vaginal discharge and spotting. For detailed benefit and risk information, consult the Cerene Instructions for use (IFU) or your healthcare professional. Learn More